ATE530575T1 - Demannosylierter rekombinanter faktor viii zur behandlung von patienten mit hämophilie a - Google Patents

Demannosylierter rekombinanter faktor viii zur behandlung von patienten mit hämophilie a

Info

Publication number
ATE530575T1
ATE530575T1 AT08762760T AT08762760T ATE530575T1 AT E530575 T1 ATE530575 T1 AT E530575T1 AT 08762760 T AT08762760 T AT 08762760T AT 08762760 T AT08762760 T AT 08762760T AT E530575 T1 ATE530575 T1 AT E530575T1
Authority
AT
Austria
Prior art keywords
demannosylated
hemophilia
patients
treatment
factor viii
Prior art date
Application number
AT08762760T
Other languages
English (en)
Inventor
Abdessatar Chtourou
Desmazes Sebastien Lacroix
Srinivas Kaveri
Suryasarathi Dasgupta
Jagaadeesh Bayry
Original Assignee
Lfb Biotechnologies
Inst Nat Sante Rech Med
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lfb Biotechnologies, Inst Nat Sante Rech Med filed Critical Lfb Biotechnologies
Application granted granted Critical
Publication of ATE530575T1 publication Critical patent/ATE530575T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C07K14/755—Factors VIII, e.g. factor VIII C (AHF), factor VIII Ag (VWF)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36—Blood coagulation or fibrinolysis factors
    • A61K38/37—Factors VIII
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biomedical Technology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biotechnology (AREA)
  • Diabetes (AREA)
  • Toxicology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
AT08762760T 2007-04-20 2008-04-21 Demannosylierter rekombinanter faktor viii zur behandlung von patienten mit hämophilie a ATE530575T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP07290495A EP1985631A1 (de) 2007-04-20 2007-04-20 Entmannosierter rekombinanter Faktor VIII zur Behandlung von Patienten mit Hämophilie A
PCT/IB2008/001417 WO2008129422A1 (en) 2007-04-20 2008-04-21 Demannosylated recombinant factor vii for the treatment of patients with haemophilia a

Publications (1)

Publication Number Publication Date
ATE530575T1 true ATE530575T1 (de) 2011-11-15

Family

ID=38515425

Family Applications (1)

Application Number Title Priority Date Filing Date
AT08762760T ATE530575T1 (de) 2007-04-20 2008-04-21 Demannosylierter rekombinanter faktor viii zur behandlung von patienten mit hämophilie a

Country Status (15)

Country Link
US (1) US8802620B2 (de)
EP (2) EP1985631A1 (de)
JP (1) JP2010524453A (de)
KR (1) KR20100017142A (de)
CN (1) CN101970481A (de)
AR (1) AR066132A1 (de)
AT (1) ATE530575T1 (de)
AU (1) AU2008240663A1 (de)
BR (1) BRPI0810592A2 (de)
CA (1) CA2684834A1 (de)
DK (1) DK2150561T3 (de)
ES (1) ES2376022T3 (de)
PL (1) PL2150561T3 (de)
TW (1) TW200914608A (de)
WO (1) WO2008129422A1 (de)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2728708A1 (en) * 2008-06-25 2009-12-30 Bayer Healthcare Llc Factor viii muteins with reduced immunogenicity
FR2933496B1 (fr) * 2008-07-02 2012-10-05 Lfb Biotechnologies Procede de mesure du taux de facteur vii active dans un echantillon
EP3008084A2 (de) * 2013-06-12 2016-04-20 Novo Nordisk A/S Verbindungen zur behandlung von hämophilie
KR20160090810A (ko) 2013-10-22 2016-08-01 디비브이 테크놀로지스 (소시에떼 아노님) 혈액 인자에 대한 관용 유도에 의한 혈우병의 치료 방법
EP3114138B1 (de) 2014-03-05 2021-11-17 Pfizer Inc. Verbesserte muteine von gerinnungsfaktor viii
AU2016343887B2 (en) * 2015-10-28 2023-04-06 Sangamo Therapeutics, Inc. Liver-specific constructs, factor VIII expression cassettes and methods of use thereof
EP3476937A4 (de) * 2016-06-24 2019-12-04 Mogam Institute for Biomedical Research Chimäres protein mit fviii- und vwf-faktoren sowie verwendung davon
US11306329B2 (en) * 2018-02-19 2022-04-19 City Of Hope Adeno-associated virus compositions for restoring F8 gene function and methods of use thereof
CN112575034B (zh) * 2019-09-29 2023-04-25 济南赛尔生物科技股份有限公司 一种治疗a型血友病的产品及应用
CN113248594B (zh) * 2021-04-26 2022-08-30 北京美康基免生物科技有限公司 一种重组凝血因子viii及其应用
WO2023092864A1 (en) * 2021-11-25 2023-06-01 Sichuan Real&Best Biotech Co., Ltd. Engineered human fviii with enhanced secretion ability and clotting activity

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4965199A (en) * 1984-04-20 1990-10-23 Genentech, Inc. Preparation of functional human factor VIII in mammalian cells using methotrexate based selection
US6060447A (en) * 1987-05-19 2000-05-09 Chiron Corporation Protein complexes having Factor VIII:C activity and production thereof
US6759216B1 (en) * 1998-11-06 2004-07-06 Emory University Glycosylated, low antigenicity low immunogenicity factor VIII
DE59914490D1 (de) * 1998-11-10 2007-10-18 Sanquin Bloedvoorziening Ein faktor viii-polypeptid mit faktor viii:c-aktivität
WO2002096454A1 (en) * 2001-05-31 2002-12-05 D. Collen Research Foundation Vzw Recombinant molecules with reduced immunogenicity, methods and intermediates for obtaining them and their use in pharmaceutical compositions and diagnostic tools
WO2005046583A2 (en) * 2003-10-30 2005-05-26 Emory University Modified fviii having reduced immunogenicity through mutagenesis of a2 and c2 epitopes
US7211559B2 (en) * 2003-10-31 2007-05-01 University Of Maryland, Baltimore Factor VIII compositions and methods

Also Published As

Publication number Publication date
PL2150561T3 (pl) 2012-03-30
EP1985631A1 (de) 2008-10-29
CN101970481A (zh) 2011-02-09
EP2150561B1 (de) 2011-10-26
TW200914608A (en) 2009-04-01
WO2008129422A1 (en) 2008-10-30
US8802620B2 (en) 2014-08-12
US20100197578A1 (en) 2010-08-05
JP2010524453A (ja) 2010-07-22
DK2150561T3 (da) 2011-12-19
ES2376022T3 (es) 2012-03-08
CA2684834A1 (en) 2008-10-30
BRPI0810592A2 (pt) 2014-10-21
AU2008240663A1 (en) 2008-10-30
WO2008129422A8 (en) 2009-11-19
AR066132A1 (es) 2009-07-22
KR20100017142A (ko) 2010-02-16
EP2150561A1 (de) 2010-02-10

Similar Documents

Publication Publication Date Title
ATE530575T1 (de) Demannosylierter rekombinanter faktor viii zur behandlung von patienten mit hämophilie a
ATE512663T1 (de) Kombination zur behandlung von erkrankungen mit zellproliferation
BR112012004546A2 (pt) "terapêutica por proteínas ligantes dll4-ligantes"
ATE447551T1 (de) Biphenyloxyessigsäure - derivate zur behandlung von atemwegserkränkungen
ATE550329T1 (de) Heterobicyclische sulfonamidderivate zur behandlung von diabetes
DE602005015577D1 (de) Harnstoff-antagonisten des p2y1-rezeptors zur behandlung von thromboseleiden
DE602006019838D1 (de) Piperazinsubstituierte benzothiophene zur behandlung von geisteskrankheiten
ZA201008720B (en) Fviii muteins for treatment of von willebrand disease
DE602008004889D1 (de) Verfahren zur herstellung von ethylenoxid und ethylenglykol
DE502006007982D1 (de) Neue arzneimittelkombinationen zur behandlung von atemwegserkrankungen
DE602005026131D1 (de) Spulengatter zur kontinuierlichen zuführung von garn
DE602006009899D1 (de) Verwendung von oxycodon zur behandlung von viszeralem schmerz
ATE534633T1 (de) Indazolderivate zur behandlung von hsp90- induzierten krankheiten
DK2310043T4 (da) Faktor VIII samt von Willebrand faktor til behandling af koagulationsdefekt in-duceret af trombocythæmmere
PT2078730E (pt) Processo para a obtenção de um concentrado do factor de von willebrand ou de um complexo factor viii/factor de von willebrand e sua utilização
ATE477798T1 (de) Verwendung von agomelatin zur herstellung von medikamenten zur behandlung der generalisierten angststörung
DE102006023680B8 (de) Verfahren zur Herstellung von großflächigem Nähgut
DE602006017367D1 (de) Amino-oxo-indolyliden-verbindungen zur verwendung in der behandlung von juckender kopfhaut
DE602005016141D1 (de) S-mirtazapin zur behandlung von hitzewallungen
ATE504297T1 (de) Visnadin zur behandlung von kopfhautjucken
ATE537178T1 (de) Neue klasse von spiro-piperidinen zur behandlung neurodegenerativer krankheiten
DE602005027251D1 (de) Sulfamide alsendothelinrezeptorantagonsiten zur behandlung von herzkreislauferkrankungen
DE602007009877D1 (de) Isosorbid-mononitrat-derivate zur behandlung von darmerkrankungen
DE102009018133A8 (de) Pharmazeutische Zusammensetzung zur Behandlung von dermatologischen Autoimmunerkrankungen
ATE516805T1 (de) Medikament zur behandlung von endometriose

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 2150561

Country of ref document: EP